Business
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million Bolstered balance sheet with $400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2025. “We are a global commercial company with multiple products generating meaningful growth that is expected to accelerate from anticipated launches from our late-stage clinical pipeline,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “We announced today that we bolstered our balance sheet with a royalty financing ahead of pivotal milestones expected over the next year to support multiple late-stage data readouts, multiple regulatory submissions, and multiple launches. This includes the highly anticipated phase 3 study readouts for UX143 in osteogenesis imperfecta around the end of the year.” Third Quarter 2025 Selected Financial Data Tables and Financial Results Revenues (dollars in thousands), (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Crysvita Product sales - Latin America and Türkiye$47,003 $35,604 $136,810 $112,294 Royalty revenue - U.S. and Canada 57,186 55,985 177,122 163,432 Royalty revenue - Europe 7,754 6,258 21,282 18,376 Total Crysvita Revenue 111,943 97,847 335,214 294,102 Dojolvi 24,275 21,374 64,491 57,091 Evkeeza 16,717 10,657 42,321 21,788 Mepsevii 6,998 9,616 23,695 22,372 Total revenues$159,933 $139,494 $465,721 $395,353 Total RevenuesUltragenyx reported $160 million in total revenue for the third quarter of 2025, which represents 15% growth compared to the same period in 2024. Crysvita revenue in the third quarter 2025 was $112 million, which includes product sales of $47 million from Latin America and Türkiye. Dojolvi revenue in the third quarter 2025 was $24 million. Evkeeza revenue in the third quarter 2025 ...